Original articleMetastatic melanomas of unknown primary show better prognosis than those of known primary: A systematic review and meta-analysis of observational studies
Section snippets
Methods
This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement.8 Firstly, a quantitative synthesis of all relevant studies that compared the prognosis of MUP with that of MKP was planned. The primary outcome of interest was overall survival (OS), which was defined as time from melanoma diagnosis to death or last follow-up. Secondary outcome was disease-free survival (DFS), defined as time from melanoma diagnosis to local or
Search results
Of the 1594 records initially identified after removing duplicates, 1500 studies were discarded because–after reviewing the titles and abstracts–it appeared that these articles clearly did not meet the prescribed criteria. A total of 94 studies were assessed in full text for eligibility (Fig 1), of which 76 were excluded for the following reasons: not about MUP (n = 9), duplicated data (n = 2), review articles (n = 4), case series or less than 10 cases (n = 14), autopsy study (n = 1),
Discussion
The condition of MUP is not rare. In this review, the proportion of MUP ranged from 1.4% to 5.6% among all patients with melanoma. MUP could be classified into 3 categories of subcutaneous, nodal, and visceral diseases, and nodal MUP was the most commonly encountered subtype ranging between 0.7% and 8.8%. However, the entity of MUP has not been fully understood, and the features of survival could be a key to delineate the condition.
This meta-analysis provides evidence that MUP has better
References (52)
- et al.
Chapter 124. Cutaneous melanoma
- et al.
Malignant melanoma of unknown primary origin
Surg Gynecol Obstet
(1963) - et al.
Malignant melanoma of unknown primary site: to make the long story short; a systematic review of the literature
Crit Rev Oncol Hematol
(2011) - et al.
Final version of 2009 AJCC melanoma staging and classification
J Clin Oncol
(2009) - et al.
End results in the treatment of malignant melanoma: a report of 1190 cases
Ann Surg
(1952) - et al.
Occult primary malignant melanoma: factors influencing survival
Br J Surg
(1977) - et al.
A multifactorial analysis of melanoma, III: prognostic factors in melanoma patients with lymph node metastases (stage II)
Ann Surg
(1981) - et al.
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
BMJ
(2009) - et al.
Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints
Stat Med
(1998) - et al.
Practical methods for incorporating summary time-to-event data into meta-analysis
Trials
(2007)
Meta-analysis in clinical trials
Control Clin Trials
Clinical aspects of unknown primary melanoma
Ann Surg
Metastatic malignant melanoma of unknown primary origin: a study of 30 cases
J Surg Oncol
Melanoma metastatic to cervical and parotid nodes from an unknown primary site
Am J Surg
Surgical treatment of lymph nodes with metastatic melanoma from unknown primary site
Arch Surg
Melanoma of unknown primary site: presentation, treatment, and prognosis–a single institution study
Cancer
Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations
Cancer
Survival of patients with visceral metastatic melanoma from an occult primary lesion: a retrospective matched cohort study
Ann Oncol
Metastatic melanoma of unknown primary site
Ann Dermatol Venereol
Metastatic melanoma to lymph nodes in patients with unknown primary sites
Cancer
Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma
J Clin Oncol
Improved survival for stage IV melanoma from an unknown primary site
J Clin Oncol
Melanoma without a detectable primary site with metastases to lymph nodes
Dermatol Surg
Melanoma of unknown primary site: a 33-year experience at the Turin Melanoma Center
Melanoma Res
Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site
Ann Surg Oncol
Melanoma with unknown primary: report and analysis of 24 patients
Med Oncol
Cited by (62)
Management of advanced stage IV melanoma of unknown primary origin with multiple visceral metastases
2024, Asian Journal of SurgeryImpact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort
2023, Journal of the American Academy of DermatologyCitation Excerpt :Finally, KIT mutations are uncommon in MUP and may differentiate them from mucosal melanomas.15-17 This biological background might confer better survival for patients with MUP compared to those with stage-matched melanoma of known primary (MKP), as suggested by a meta-analysis and several retrospective studies conducted before the era of novel therapies.4,18-20 However, contradictory findings have also been reported, suggesting an equal or worse prognosis for patients with MUP.21-23
A rare case of endobronchial melanoma of unknown primary
2023, Respiratory Medicine Case ReportsThoracic metastasis of malignant melanoma of unknown primary: A case report and literature review
2021, International Journal of Surgery Case ReportsCitation Excerpt :Although more than 90% of melanomas have a cutaneous origin, occasionally it is discovered first as a secondary deposit, lymph node or visceral, without evident primary site. This entity of melanoma of unknown primary was initially characterized by Das Gupta in 1963 who was the first to describe the criteria for MUP [1,3]. Metastatic melanoma of unknown primary is a melanocytic lesion in distant sites in the absence of apparent skin involvement and is rare, accounting for up to 3,2% of all incident melanomas as well as being yet poorly understood in terms of pathogenesis.
Melanoma of unknown primary: New perspectives for an old story
2021, Critical Reviews in Oncology/HematologyCitation Excerpt :Moreover, it is anticipated that there are survival differences between nodal and visceral MUP patients (Pfeil et al., 2011; Muchmore et al., 1986; Anbari et al., 1997; Katz et al., 2005; Reintgen et al., 1983; Velez et al., 1991; Schlagenhauff et al., 1997; Chang et al., 1998; De Waal et al., 2013). The favorable survival of MUP compared to MKP has also been highlighted in the meta-analysis by Bae et al. (Bae et al., 2015). The authors reported better OS for both stage III (HR 0.83, 95 % CI 0.73–0.96, p = 0.01) and stage IV MUP patients (HR 0.85, 95 % CI 0.75–0.96, p = 0.08), compared to MKP cohorts, respectively.
Melanoma of unknown primary origin with skeletal muscle metastasis: a case report
2023, Journal of Medical Case Reports
Drs Bae and Choi contributed equally to this work.
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2013R1A2A2A04015894).
Conflicts of interest: None declared.